http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
신합성 물질인 Protein kinase A 억제제, H-87의 MDR1 유전자 발현의 조절
박주인,김선희,정병선 부산대학교 유전공학연구소 1992 분자생물학 연구보 Vol.8 No.-
In this study, we examined the effect of H-87, specific inhibitor of protein kinase A, on in vitro sensitivities of mouse leukemia cell line P388 resistant to several antitumor agents. H-87 significantly potentiated the cytotoxic effects of ADM, VCR and VBL on P388 cells resistant to these antitumor agents. Thus we examined the mechanism of overcoming multidrug resistance by H-87. In northern blot analysis, H-87-treated resistant P388 cell lines showed less MDR1 gene expression than untreated control cells. As a result of CAT assay, the expression of MDRI promoter was inhibited by H-87 in a concentration-dependent manner. To compare the effect of H-87 with that of staurosporine(PKC inhibitor), we examined the effect of staurosporine on in vitro sensitivities of mouse leukemia cell line resistant to several antitumor agents. The expression of MDR1 gene in multidrug resistant P388 cells was decreased by staurosporine. The activity of MDR1 promoter was increased by TPA(PKC activator) and forskolin(adenylate cyclase activator). Therefore, we speculate that PKA and PKC may play important roles in the regulation of MDRI gene expression.
박주인,류지욱,박창규,박봉진,이봉암,최석근 대한정위기능신경외과학회 2023 대한정위기능신경외과학회지 Vol.19 No.2
ObjectiveWe analyzed the clinical outcomes of Meckel’s cave compression with Teflon (Rhee’s method) as a new modified and additional surgical technique for trigeminal neuralgia (TN). MethodsBetween March 1996 and December 2014, out of 78 patients who were treated with microvascular decompression (MVD) or partial sensory root rhizotomy, 28 patients additionally underwent Meckel’s cave compression with Teflon. The mean age at initial treatment was 54.3 years (range: 40-69 years). The mean duration from onset to operation was 70.5 months (range: 5-360 months) and the mean follow-up period was 26 months (range: 1-77 months). ResultsFifteen patients (53.6%) had facial pain in the V2/V3 distribution. The offending or associating vessel was the superior cerebellar artery in four patients (14.3%), the superior petrosal vein in six (21.4%), the anterior inferior cerebellar artery in two (7.1%), multiple vessels in nine (32.1%), and miscellaneous arteries or veins in six (21.4%). One patient (3.6%) had no offending vessel, and seven patients were had no definite offending vessels that contacted the trigeminal root entry zone. Meckel’s cave compression with Teflon was applied to all patients: 10 (35.7%) in combination with MVD, one (3.6%) with partial rhizotomy, and 17 (60.7%) with both MVD and partial rhizotomy. TN was relieved in 26 patients (92.9%) and symptoms recurred in three patients. The complication rate of this method appeared to be similar to other treatment procedures. ConclusionMeckel’s cave compression with Teflon may be a safe and useful additional treatment procedure for TN.